InternationalUSRemember you can easily switch between MIP US and MIP International at any time

Chugai wins licence dispute concerning US patent in UK High Court

Patrick Wingrove, London


The English High Court has ruled that Chugai no longer needs to pay royalties for its antibody product because it does not fall within the claims of UCB’s US patent

In a decision that nicely summarises US law and provides lessons on licence and patent drafting, the UK High Court has ruled that Chugai does not need to pay royalties to UCB for its tocilizumab products.

Mr Justice Birss decided...


Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain FREE access to up to five free articles when you register now.

Join here

More from the Managing IP blog


null null null

null null null

null

Most read articles

Supplements